Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab versus nivolumab monotherapy in previously untreated advanced renal cell carcinoma (intermediate/poor risk)
2018-004695-35Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Nivolumab + ipilimumab with Nivolumab + placebo (2 arms). Primary endpoint: Progression-free survival by BICR. Started Apr 2019; status: active.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2018-004695-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004695-35.